Abstract：
Denosumab has been considered a treatment option for Central Giant Cell Granuloma (CGCG) a benign locally aggressive osteolytic lesion of the jaws. This study aimed to perform a scoping review of CGCG treated with Denosumab. The research question was: What is Denosumab\'s effectiveness in treating CGCG of the jaws? Studies that used Denosumab as a treatment for CGCGs in the jaws were selected following PRISMA-ScR guidelines, using Pubmed/Medline, Scopus, and Springer Link databases, among others. Demographics, clinical information, dosing, efficacy, adverse drug reactions (ADRs), and imaging tests used to assess the evolution of the lesions were extracted. Twenty-one studies were selected. Sixty patients with a mean age of 23.2 years were treated with Denosumab, 42% with 120 mg subcutaneously monthly, additional doses on days 1, 8, and 15 for month 1 in adults. In children, dosing was adjusted by weight to 60 or 70 mg. To avoid ADRs 500 mg of calcium and 400 IU of vitamin D orally were used. Initial effective response was reported after 1-3 months, with recurrence of 19.6% and ADRs in 74% of cases. Denosumab is effective for CGCG with monthly subcutaneous doses of 120 mg, 60 or 70 mg in patients < 45 or 50 kg for ≥ 12 months with calcium and vitamin D supplementation until remission changes are observed. Extensive or refractory lesions were the main indications. Common ADRs were hypo and hypercalcemia. Further studies are needed to define dose and supplementation protocols to avoid ADRs during and after therapy.
摘要：
Denosumab已被认为是中央巨细胞肉芽肿（CGCG）的一种治疗选择，这是颌骨的良性局部侵袭性溶骨性病变。本研究旨在对用Denosumab治疗的CGCG进行范围审查。Theresearchquestionwas:WhatisDenosumab’sefficientintreatingCGCGofthejaws?StudiesthatusedDenosumabasatreatmentforCGCGinthejawswereselectedfollowingPRISMA-ScRguidelines,使用Pubmed/Medline，Scopus,和SpringerLink数据库,在其他人中。人口统计,临床信息，给药,功效,药物不良反应（ADR），并提取用于评估病变演变的影像学检查。选择了21项研究。60名平均年龄为23.2岁的患者接受了Denosumab治疗，42%每月皮下120毫克，在成人第1、8和15天的第1个月额外剂量。在儿童中，剂量按重量调整至60或70mg。为了避免ADR，口服500毫克钙和400IU维生素D。最初的有效反应是在1-3个月后报告的，复发率为19.6%，不良反应发生率为74%。Denosumab对CGCG有效，每月皮下剂量为120毫克，60或70mg<45或50kg的患者持续≥12个月，补充钙和维生素D直至观察到缓解变化。广泛或难治性病变是主要适应症。常见的不良反应为低钙血症和高钙血症。需要进一步的研究来确定剂量和补充方案，以避免治疗期间和之后的ADR。
